# PTPN2

## Overview
PTPN2 is a gene that encodes the protein tyrosine phosphatase non-receptor type 2 (PTPN2), a crucial enzyme involved in the regulation of various cellular signaling pathways. As a member of the protein tyrosine phosphatase family, PTPN2 functions primarily as a signaling molecule that dephosphorylates specific tyrosine residues on target proteins, thereby modulating their activity. This protein plays a significant role in immune regulation, particularly in T cell signaling, where it helps maintain immune tolerance and prevent autoimmunity by setting thresholds for T cell receptor activation (Wiede2011T). PTPN2 is also involved in cytokine signaling pathways, such as the JAK/STAT pathway, and has been implicated in the pathogenesis of autoimmune diseases like type 1 diabetes and Crohn's disease (Sharp2015Genetic; Wiede2014PTPN2). The protein's ability to interact with various kinases and receptors underscores its importance in both immune and cancer-related signaling pathways (Veenstra2019The; Song2022PTPN2).

## Structure
PTPN2 encodes a protein tyrosine phosphatase involved in various cellular signaling pathways. The primary structure of PTPN2 consists of a sequence of amino acids that form the protein, which includes a phosphatase domain crucial for its enzymatic activity (Hao2024Mechanistic). The secondary structure of PTPN2 is characterized by the presence of alpha helices and beta sheets, which contribute to the protein's stability and function. The tertiary structure involves the three-dimensional folding of the protein, allowing it to interact with specific substrates and regulatory proteins (Hao2024Mechanistic).

PTPN2 is known to undergo post-translational modifications, such as phosphorylation, which can modulate its activity and interactions with other proteins (Hao2024Mechanistic). The protein also has splice variant isoforms, which may affect its function and localization within the cell (Hao2024Mechanistic).

In terms of quaternary structure, PTPN2 can form complexes with other proteins, such as the CRBN-DDB1 E3 ligase complex, facilitated by heterobifunctional degraders like Cmpd-1 and Cmpd-2. These interactions are crucial for the protein's role in cellular signaling and degradation pathways (Hao2024Mechanistic).

## Function
The PTPN2 gene encodes the protein tyrosine phosphatase non-receptor type 2 (PTPN2), which plays a critical role in regulating T cell signaling and maintaining immune tolerance. In healthy human cells, PTPN2 is involved in dephosphorylating and inactivating Src family kinases, such as Lck and Fyn, which are essential for T cell receptor (TCR) signaling. This action helps to set the threshold for TCR-induced naive T cell responses, preventing excessive activation that could lead to autoimmunity (Wiede2011T).

PTPN2 is also involved in regulating cytokine signaling pathways, including the JAK/STAT pathway, by dephosphorylating Janus-activated kinases and several STAT family members. This regulation is crucial for maintaining immune homeostasis and preventing chronic inflammatory and autoimmune disorders (Wiede2014PTPN2).

In the thymus, PTPN2 regulates positive selection and controls lymphopenia-induced proliferation in CD8+ T cells, ensuring a balanced T cell repertoire and preventing the development of autoimmune phenotypes (Spalinger2015PTPN2). PTPN2's activity in both the cytoplasm and nucleus influences key signaling pathways, impacting inflammation and metabolism (Wiede2011T).

## Clinical Significance
Mutations and alterations in the PTPN2 gene are associated with several autoimmune and inflammatory diseases. PTPN2 is implicated in the pathogenesis of type 1 diabetes (T1D) and Crohn's disease. In T1D, PTPN2 deficiency in T cells leads to enhanced T cell receptor (TCR) responses to self-antigens, promoting autoimmunity and accelerating disease onset in NOD mice (Wiede2019TCell–Specific). Loss of PTPN2 function is linked to increased beta cell apoptosis, influenced by type I and II interferons, which exacerbates T1D (Sharp2015Genetic).

In Crohn's disease, PTPN2 loss results in increased pro-inflammatory mediators, aberrant T cell differentiation, and intestinal dysbiosis. This leads to an imbalance in T helper cell populations, with increased Th1 and Th17 cells and decreased regulatory T cells, promoting intestinal inflammation (Sharp2015Genetic; Spalinger2015PTPN2). Variants such as rs2542151 and rs7234029 are associated with increased susceptibility to Crohn's disease and ulcerative colitis, indicating a common genetic background for these conditions (Glas2012PTPN2).

PTPN2 also plays a role in regulating autophagosome formation, and its deficiency impairs autophagy, exacerbating intestinal inflammation (Sharp2015Genetic). These findings highlight the critical role of PTPN2 in maintaining immune tolerance and preventing systemic inflammation.

## Interactions
PTPN2, also known as protein tyrosine phosphatase non-receptor type 2, is involved in several critical interactions with other proteins, influencing various signaling pathways. It dephosphorylates receptor and non-receptor protein tyrosine kinases, including the epidermal growth factor receptor (EGFR), colony-stimulating factor 1 receptor (CSF1R), platelet-derived growth factor receptor (PDGFR), and insulin receptor (IR), as well as non-receptor kinases such as JAK, Src, and STAT family kinases (Song2022PTPN2). PTPN2 interacts with the Src family kinases LCK and FYN, dephosphorylating them to regulate T cell receptor (TCR) signaling, which is crucial for T cell development and function (Liang2023A; Wiede2011T).

PTPN2 also plays a role in modulating cytokine signaling by dephosphorylating Janus-activated kinases (JAK)-1 and JAK-3, and their substrates STAT-1, STAT-3, and STAT-5, impacting immune responses and cell growth (Wiede2019PTPN; Song2022PTPN2). In the context of cancer, PTPN2 interacts with the Met receptor, affecting its phosphorylation status and influencing breast cancer progression (Veenstra2019The). These interactions highlight PTPN2's role as a key regulator in immune and cancer-related signaling pathways.


## References


[1. (Liang2023A) Shuwei Liang, Eric Tran, Xin Du, Jiajun Dong, Harrison Sudholz, Hao Chen, Zihan Qu, Nicholas D. Huntington, Jeffrey J. Babon, Nadia J. Kershaw, Zhong-Yin Zhang, Jonathan B. Baell, Florian Wiede, and Tony Tiganis. A small molecule inhibitor of ptp1b and ptpn2 enhances t cell anti-tumor immunity. Nature Communications, July 2023. URL: http://dx.doi.org/10.1038/s41467-023-40170-8, doi:10.1038/s41467-023-40170-8. This article has 27 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-40170-8)

[2. (Sharp2015Genetic) Robert C. Sharp, Muna Abdulrahim, Ebraheem S. Naser, and Saleh A. Naser. Genetic variations of ptpn2 and ptpn22: role in the pathogenesis of type 1 diabetes and crohn’s disease. Frontiers in Cellular and Infection Microbiology, December 2015. URL: http://dx.doi.org/10.3389/fcimb.2015.00095, doi:10.3389/fcimb.2015.00095. This article has 57 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcimb.2015.00095)

[3. (Wiede2019PTPN) Florian Wiede, Kun‐Hui Lu, Xin Du, Shuwei Liang, Katharina Hochheiser, Garron T Dodd, Pei K Goh, Conor Kearney, Deborah Meyran, Paul A Beavis, Melissa A Henderson, Simone L Park, Jason Waithman, Sheng Zhang, Zhong‐Yin Zhang, Jane Oliaro, Thomas Gebhardt, Phillip K Darcy, and Tony Tiganis. <scp>ptpn</scp> 2 phosphatase deletion in t cells promotes anti‐tumour immunity and <scp>car</scp> t‐cell efficacy in solid tumours. The EMBO Journal, December 2019. URL: http://dx.doi.org/10.15252/embj.2019103637, doi:10.15252/embj.2019103637. This article has 92 citations.](https://doi.org/10.15252/embj.2019103637)

[4. (Veenstra2019The) Cynthia Veenstra, Elin Karlsson, Sanam Mirwani Mirwani, Bo Nordenskjöld, Tommy Fornander, Gizeh Pérez-Tenorio, and Olle Stål. The effects of ptpn2 loss on cell signalling and clinical outcome in relation to breast cancer subtype. Journal of Cancer Research and Clinical Oncology, 145(7):1845–1856, April 2019. URL: http://dx.doi.org/10.1007/s00432-019-02918-y, doi:10.1007/s00432-019-02918-y. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00432-019-02918-y)

[5. (Spalinger2015PTPN2) M R Spalinger, S Kasper, C Chassard, T Raselli, I Frey-Wagner, C Gottier, S Lang, K Atrott, S R Vavricka, F Mair, B Becher, C Lacroix, M Fried, G Rogler, and M Scharl. Ptpn2 controls differentiation of cd4+ t cells and limits intestinal inflammation and intestinal dysbiosis. Mucosal Immunology, 8(4):918–929, July 2015. URL: http://dx.doi.org/10.1038/mi.2014.122, doi:10.1038/mi.2014.122. This article has 83 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/mi.2014.122)

[6. (Glas2012PTPN2) Jürgen Glas, Johanna Wagner, Julia Seiderer, Torsten Olszak, Martin Wetzke, Florian Beigel, Cornelia Tillack, Johannes Stallhofer, Matthias Friedrich, Christian Steib, Burkhard Göke, Thomas Ochsenkühn, Nazanin Karbalai, Julia Diegelmann, Darina Czamara, and Stephan Brand. Ptpn2 gene variants are associated with susceptibility to both crohn’s disease and ulcerative colitis supporting a common genetic disease background. PLoS ONE, 7(3):e33682, March 2012. URL: http://dx.doi.org/10.1371/journal.pone.0033682, doi:10.1371/journal.pone.0033682. This article has 53 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0033682)

[7. (Hao2024Mechanistic) Qi Hao, Manoj K. Rathinaswamy, Kelly L. Klinge, Matthew Bratkowski, Amirhossein Mafi, Christina K. Baumgartner, Keith M. Hamel, Gesine K. Veits, Rinku Jain, Claudio Catalano, Mark Fitzgerald, Alexander W. Hird, Eunice Park, Harit U. Vora, James A. Henderson, Kenton Longenecker, Charles W. Hutchins, Wei Qiu, Giovanna Scapin, Qi Sun, Vincent S. Stoll, Chaohong Sun, Ping Li, Dan Eaton, David Stokoe, Stewart L. Fisher, Christopher G. Nasveschuk, Marcia Paddock, and Michael E. Kort. Mechanistic insights into a heterobifunctional degrader-induced ptpn2/n1 complex. Communications Chemistry, August 2024. URL: http://dx.doi.org/10.1038/s42004-024-01263-7, doi:10.1038/s42004-024-01263-7. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s42004-024-01263-7)

[8. (Wiede2014PTPN2) Florian Wiede, Nicole L. La Gruta, and Tony Tiganis. Ptpn2 attenuates t-cell lymphopenia-induced proliferation. Nature Communications, January 2014. URL: http://dx.doi.org/10.1038/ncomms4073, doi:10.1038/ncomms4073. This article has 52 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms4073)

[9. (Wiede2011T) Florian Wiede, Benjamin J. Shields, Sock Hui Chew, Konstantinos Kyparissoudis, Catherine van Vliet, Sandra Galic, Michel L. Tremblay, Sarah M. Russell, Dale I. Godfrey, and Tony Tiganis. T cell protein tyrosine phosphatase attenuates t cell signaling to maintain tolerance in mice. Journal of Clinical Investigation, 121(12):4758–4774, December 2011. URL: http://dx.doi.org/10.1172/jci59492, doi:10.1172/jci59492. This article has 181 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci59492)

[10. (Wiede2019TCell–Specific) Florian Wiede, Thomas C. Brodnicki, Pei Kee Goh, Yew A. Leong, Gareth W. Jones, Di Yu, Alan G. Baxter, Simon A. Jones, Thomas W.H. Kay, and Tony Tiganis. T-cell–specific ptpn2 deficiency in nod mice accelerates the development of type 1 diabetes and autoimmune comorbidities. Diabetes, 68(6):1251–1266, April 2019. URL: http://dx.doi.org/10.2337/db18-1362, doi:10.2337/db18-1362. This article has 31 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.2337/db18-1362)

[11. (Song2022PTPN2) Jiachun Song, Jinxin Lan, Jiaping Tang, and Na Luo. Ptpn2 in the immunity and tumor immunotherapy: a concise review. International Journal of Molecular Sciences, 23(17):10025, September 2022. URL: http://dx.doi.org/10.3390/ijms231710025, doi:10.3390/ijms231710025. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms231710025)